About EGB Capital

Opeator is a fermentation technology company that utilizes an anaerobic process to enhance the efficiency and scalability of industrial fermentation. By enabling extended fermentation runs and employing low-cost bioreactors, the company improves process robustness and reduces operational costs for various industries.

```xml <problem> Traditional industrial fermentation processes rely on oxygen, requiring complex and costly systems for aeration and mixing in bioreactors. These systems limit scalability, increase capital expenditures, and complicate process design. </problem> <solution> Izote Biosciences offers a fermentation technology that utilizes an alternative molecule to oxygen, enabling anaerobic biomanufacturing. This approach simplifies fermentation design, reduces the need for traditional aeration methods, and allows for extended fermentation runs. By eliminating the requirement for air compressors, blowers, and agitators, Izote's technology reduces operational and capital expenses while improving process robustness. The system facilitates predictable scaling of performance and enables the use of low-cost bioreactors and feedstocks. </solution> <features> - Anaerobic fermentation process using a highly soluble alternative molecule to oxygen - Simplified bioreactor design, eliminating the need for complex aeration systems - Enables extended fermentation runs for increased productivity - Highly predictable scaling of performance from lab to industrial scale - Compatible with low-cost bioreactors and feedstocks - Reduces operational expenses by up to 50% - Reduces energy consumption by up to 70% - Reduces capital expenditures by up to 90% </features> <target_audience> The primary customers are companies in the fragrance, pharmaceutical, and specialty chemical industries seeking to manufacture small molecules and proteins more efficiently and cost-effectively. </target_audience> ```

What does EGB Capital do?

Where is EGB Capital located?

EGB Capital is based in Berkeley, United States.

When was EGB Capital founded?

EGB Capital was founded in 2018.

How much funding has EGB Capital raised?

EGB Capital has raised 2600000.

Location

Berkeley, United States

Founded

2018

Funding

2600000

Employees

1 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

EGB Capital

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

izote.bio 10+

Founded 2018 – Berkeley, United States

Funding

Estimated Funding

$2M+

Team (<5)

No team information available.

Company Description

Problem

Traditional industrial fermentation processes rely on oxygen, requiring complex and costly systems for aeration and mixing in bioreactors. These systems limit scalability, increase capital expenditures, and complicate process design.

Solution

Izote Biosciences offers a fermentation technology that utilizes an alternative molecule to oxygen, enabling anaerobic biomanufacturing. This approach simplifies fermentation design, reduces the need for traditional aeration methods, and allows for extended fermentation runs. By eliminating the requirement for air compressors, blowers, and agitators, Izote's technology reduces operational and capital expenses while improving process robustness. The system facilitates predictable scaling of performance and enables the use of low-cost bioreactors and feedstocks.

Features

Anaerobic fermentation process using a highly soluble alternative molecule to oxygen

Simplified bioreactor design, eliminating the need for complex aeration systems

Enables extended fermentation runs for increased productivity

Highly predictable scaling of performance from lab to industrial scale

Compatible with low-cost bioreactors and feedstocks

Reduces operational expenses by up to 50%

Reduces energy consumption by up to 70%

Reduces capital expenditures by up to 90%

Target Audience

The primary customers are companies in the fragrance, pharmaceutical, and specialty chemical industries seeking to manufacture small molecules and proteins more efficiently and cost-effectively.